Literature DB >> 3047926

Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients.

L Ost1, G Tydén, I Fehrman.   

Abstract

In 33 renal transplant patients, an intravenous glucose tolerance test (IVGTT) was performed, and fasting plasma C-peptide concentrations analyzed. Nineteen of the patients were on treatment with cyclosporine-prednisolone (CsA-Po), and 14 were treated with azathioprine-prednisolone (Aza-Po). In the Aza-Po group, the K-values at IVGTT were normal in 13/14, but in the CsA-Po group they were only normal in 9/19 (P = 0.02). The fasting C-peptide levels were significantly higher in the CsA-Po group (P less than 0.001). within this group, there was no correlation between C-peptide level and serum-creatinine concentration, i.e. retention of C-peptide due to decreased renal function as judged by serum creatinine level was not suspected. Intrinsic prednisolone clearance was determined in the CsA-Po patients and was found to be lower than that previously described in Aza-Po patients. However, between those CsA-Po-treated patients with a pathologic K-value at IVGTT and those with a normal K-value there was no difference in prednisolone clearance, fasting C-peptide levels, CsA dose, or serum-creatinine concentrations. The pathophysiology of the cyclosporine-induced glucose intolerance is uncertain, and increased insulin resistance is possible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3047926     DOI: 10.1097/00007890-198809000-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice.

Authors:  C Ricordi; Y Zeng; R Alejandro; A Tzakis; P Carroll; H L Rilo; R Venkataramanan; J J Fung; D Bereiter; T E Starzl
Journal:  Transplant Proc       Date:  1992-06       Impact factor: 1.066

2.  Oral glucose tolerance test in liver recipients treated with FK 506.

Authors:  L Mieles; S Todo; J J Fung; A Jain; H Furukawa; M Susuki; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

3.  Kidney transplantation under FK 506 immunosuppression.

Authors:  R Shapiro; M Jordan; J Fung; J McCauley; J Johnston; Y Iwaki; A Tzakis; T Hakala; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients.

Authors:  L Mieles; R D Gordon; D Mintz; R M Toussaint; O Imventarza; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

6.  In vivo effect of FK506 on human pancreatic islets.

Authors:  C Ricordi; Y J Zeng; R Alejandro; A Tzakis; R Venkataramanan; J Fung; D Bereiter; D H Mintz; T E Starzl
Journal:  Transplantation       Date:  1991-09       Impact factor: 4.939

Review 7.  Obesity and metabolic syndrome in kidney transplantation.

Authors:  Heather LaGuardia; Rubin Zhang
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

8.  Insulin action and insulin binding following pancreas transplantation.

Authors:  F Saudek; T Pelikánová; V Bartos; I Reneltová; L Kazdová; J Kovár; L Karasová
Journal:  Diabetologia       Date:  1991-08       Impact factor: 10.122

Review 9.  Endocrine and metabolic abnormalities following kidney transplantation.

Authors:  W H Hörl; W Riegel; C Wanner; M Haag-Weber; P Schollmeyer; H Wieland; H Wilms
Journal:  Klin Wochenschr       Date:  1989-09-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.